+16%

est. 2Y upside i

HealthcareSeries A

Introducing the industry's first Care Readiness Platform. Silna handles all prior authorizations, benefit checks and insurance monitoring upfront to make sure your patients are clear to receive care, and you have more capacity to provide it.

Rank

#1710

Sector

HealthTech

Est. Liquidity

~4Y

Data Quality

Data: Low

For a job candidate, the equity opportunity carries significant upside potential but high risk due to early stage and intense competition.

Last updated: July 3, 2026

Bull (10%)+130%

Silna successfully scales customer base and raises Series B at 2.5x current valuation ($280M) driven by AI category leadership and strong market demand. After ~20% dilution, effective upside is 130%.

Base (55%)+30%

Steady execution leads to Series B at 1.5x valuation ($168M) with moderate revenue growth. Dilution of 20% reduces upside to ~30%.

Bear (35%)-40%

Incumbent competition intensifies and growth disappoints; valuation contracts to $89.6M (0.8x) due to lower multiples. Preference stack not triggered but dilution leads to -40% loss.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Funding Intensity

29%

Total funding of $32.1M represents 28.7% of current $112M valuation, indicating high preference overhang.

Dilution Risk

high

A Series B round within 24 months is likely, potentially diluting common stock by 15-25%.

Secondary Liquidity

none

No secondary market activity reported; liquidity likely only via acquisition or IPO.

Questions to Ask at the Interview

Strategic questions based on Silna's data — designed to show you've done your homework.

  • 1

    “How does Silna's AI-driven prior authorization process differentiate from incumbents like Waystar or ModMed?”

  • 2

    “What is the current annual recurring revenue (ARR) and growth trajectory?”

  • 3

    “What is the expected timeline for Series B and how will that affect employee equity dilution?”

Community

Valuation Sentiment

Our model estimates +16% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.